Opting Out of the Numbers Game

As a long-time student of the scientific journal, I have witnessed incidences of unwarranted co-authorship, repeated publication of the same work, and the practice of "salami science"—the slicing of a single research project into its least publishable units. In large part, such behavior by authors can be ascribed to a growing and long excessive pressure to publish in great quantity. This pressure has also been cited as contributing to recent, notorious cases of scientific fraud. Unfortunat

Written byEugene Garfield
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

A good alternative has been suggested. Marcia Angell, deputy editor of the New England Journal of Medicine, and DeWitt Stetten, of the National Institutes of Health, have independently suggested that a ceiling be placed on the number of works a committee considers in making promotion and grant decisions. Angell has proposed that a peer-review board examine "only, at most, the three articles the candidate considers to be his or her best in any given year, with a maximum of perhaps ten in any 5-year period. Other publications should not even be listed." (Annals of Internal Medicine 104, February 1986, 262.) Stetten has suggested, "Let the applicant select, say, one dozen of his bibliographic citations that are most meaningful to him." He added, "in this regard it may be pointed out that … nomination to membership in the National Academy of Sciences requires a selective bibliography of no more than 12 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies